WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Tuesday, March 28, 2006

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L17	L2 same L16	1
☐	L16	(gene or sequence or polynucleotide)same L15	5
☐	L15	((sphingosine-1-phosphate with phosphatase) (dihydrosphingosine-1-phosphate with phosphatase) or YSR2)	12
☐	L14	l2 same L13	2
☐	L13	(gene or sequence or polynucleotide)same L12	8292
☐	L12	((sphingosine with kinase) or SK or LCB4)	890963
☐	L11	l2 same L10	6
☐	L10	(gene or sequence or polynucleotide)same L9	51
☐	L9	((dihydrosphingosine-1-phosphate with lyase) or (sphingosine-1-phosphate with lyase) or DPL1)	146
☐	L8	(sphingolipid or sphingo$7)same L7	7
☐	L7	express$5 same L4	41
☐	L6	L1 same L4	5
☐	L5	L2 same L4	1
☐	L4	(gene or sequence or polynucleotide)same L3	131
☐	L3	(sphk1 or sk1 or (spingosine with kinase$3))	1055
☐	L2	(sphingolipid or sphingo$7)same L1	94
☐	L1	((mutant with yeast with strain) or (mutant with strain) or (yeast with strain))	33230

END OF SEARCH HISTORY

=> index bioscience medicine

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 13:51:19 ON 28 MAR 2006

73 FILES IN THE FILE LIST IN STNINDEX

=> s ((mutant(w)yeast(w)strain#)or (mutant(w)strain#)or (yeast(w)strain#))
25 FILE ADISCTI
35 FILE ADISINSIGHT
4 FILE ADISNEWS
2713 FILE AGRICOLA
47 FILE ANABSTR
60 FILE ANTE
57 FILE AQUALINE
406 FILE AQUASCI
2946 FILE BIOENG
17326 FILE BIOSIS
3970 FILE BIOTECHABS
3970 FILE BIOTECHDS
7582 FILE BIOTECHNO
3588 FILE CABA
20816 FILE CAPLUS
1174 FILE CEABA-VTB
100 FILE CIN
105 FILE CONFSCI
34 FILE CROPB
237 FILE CROPU
20 FILES SEARCHED...
125 FILE DDFB
385 FILE DDFU
5012 FILE DGENE
1623 FILE DISSABS
125 FILE DRUGB
713 FILE DRUGU
115 FILE EMBAL
10586 FILE EMBASE
7179 FILE ESBIOBASE
477 FILE FEDRIP
970 FILE FROSTI
3377 FILE FSTA
1398 FILE GENBANK
36 FILES SEARCHED...
19 FILE HEALSAFE
1349 FILE IFIPAT
7 FILE IMSDRUGNEWS
15 FILE IMSRESEARCH
928 FILE JICST-EPLUS
20 FILE KOSMET
9548 FILE LIFESCI
28380 FILE MEDLINE
66 FILE NIOSHTIC
173 FILE NTIS
43 FILE OCEAN
5075 FILE PASCAL
18 FILE PCTGEN
13 FILE PHAR
4 FILE PHARMAML
68 FILE PHIN
536 FILE PROMT
61 FILE PROUSDDR
2 FILE RDISCLOSURE
11453 FILE SCISEARCH
11681 FILE TOXCENTER
13500 FILE USPATFULL
847 FILE USPAT2

```
     5  FILE VETB
   102  FILE VETU
 66 FILES SEARCHED...
    53  FILE WATER
  1857  FILE WPIDS
    17  FILE WPIFV
  1857  FILE WPINDEX
    30  FILE IPA
    94  FILE NAPRALERT
   353  FILE NLDB

 65 FILES HAVE ONE OR MORE ANSWERS,  73 FILES SEARCHED IN STNINDEX

L1  QUE ((MUTANT(W) YEAST(W) STRAIN#) OR (MUTANT(W) STRAIN#) OR (YEAST(W) STRA
    IN#))

=> d rank
F1     28380  MEDLINE
F2     20816  CAPLUS
F3     17326  BIOSIS
F4     13500  USPATFULL
F5     11681  TOXCENTER
F6     11453  SCISEARCH
F7     10586  EMBASE
F8      9548  LIFESCI
F9      7582  BIOTECHNO
F10     7179  ESBIOBASE
F11     5075  PASCAL
F12     5012  DGENE
F13     3970  BIOTECHABS
F14     3970  BIOTECHDS
F15     3588  CABA
F16     3377  FSTA
F17     2946  BIOENG
F18     2713  AGRICOLA
F19     1857  WPIDS
F20     1857  WPINDEX
F21     1623  DISSABS
F22     1398  GENBANK
F23     1349  IFIPAT
F24     1174  CEABA-VTB

=> file f1-f11, f15, f17-f19

FILE 'MEDLINE' ENTERED AT 13:55:23 ON 28 MAR 2006

FILE 'CAPLUS' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 13:55:23 ON 28 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'USPATFULL' ENTERED AT 13:55:23 ON 28 MAR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 ACS

FILE 'SCISEARCH' ENTERED AT 13:55:23 ON 28 MAR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 13:55:23 ON 28 MAR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.
```

FILE 'ESBIOBASE' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'PASCAL' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'CABA' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 CAB INTERNATIONAL (CABI)

FILE 'BIOENG' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'AGRICOLA' ENTERED AT 13:55:23 ON 28 MAR 2006

FILE 'WPIDS' ENTERED AT 13:55:23 ON 28 MAR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

=> s L1
L2 154230 L1

=> s (sphingolipid# or sphingo?)(s)L2
L3 351 (SPHINGOLIPID# OR SPHINGO?)(S) L2

=> s (sphk1 or sk1 or (sphingosine(w)kinase?))
L4 5440 (SPHK1 OR SK1 OR (SPHINGOSINE(W) KINASE?))

=> s L3(s)L4
L5 4 L3(S) L4

=> s (gene or sequence or polynucleotide or clone or recombinant)(s)L4
9 FILES SEARCHED...
L6 970 (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(S)
L4

=> s express/ (s)L6
'EXPRESS/ ' IS NOT A VALID FIELD CODE
For a list of field codes for the current file, enter "HELP SFIELDS"
at an arrow prompt (=>).

=> s express?(s)L6
13 FILES SEARCHED...
L7 442 EXPRESS?(S) L6

=> s (sphingolipid# or sphingo?)(s)L7
L8 234 (SPHINGOLIPID# OR SPHINGO?)(S) L7

=> s L8(s)L2
L9 1 L8(S) L2

=> s ((dihydrosphingosine-1-phosphate(w)lyase) or (sphingosine-1-phosphate(w)lyase) or DPL1)
10 FILES SEARCHED...
L10 442 ((DIHYDROSPHINGOSINE-1-PHOSPHATE(W) LYASE) OR (SPHINGOSINE-1-PHO
SPHATE(W) LYASE) OR DPL1)

=> s (gene or sequence or polynucleotide or clone or recombinant)(s)L10
9 FILES SEARCHED...
L11 172 (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(S)
L10

=> s L2(s)L11
L12 21 L2(S) L11

=> s (sphingolipid# or sphingo?)(s)L12
L13 21 (SPHINGOLIPID# OR SPHINGO?)(S) L12

=> s ((sphingosine(w0kinase#)or sk or LCB4)
MISSING OPERATOR 'PHINGOSINE(W0KINASE#'
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s ((sphingosine(w)kinase#)or sk or LCB4)
L14 94558 ((SPHINGOSINE(W) KINASE#) OR SK OR LCB4)

=> s (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(S)L14
9 FILES SEARCHED...
L15 16881 (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(S)
L14

=> s (sphingolipid# or sphingo?)(s)L15
L16 463 (SPHINGOLIPID# OR SPHINGO?)(S) L15

=> s L16(s)L2
L17 5 L16(S) L2

=> s ((sphingosine-1-phosphate(w)phosphatase#) or (dihydrosphingosine-1-phosphate(w)phosphatase#) or YSR2)
10 FILES SEARCHED...
L18 223 ((SPHINGOSINE-1-PHOSPHATE(W) PHOSPHATASE#) OR (DIHYDROSPHINGOSIN
E-1-PHOSPHATE(W) PHOSPHATASE#) OR YSR2)

=> s (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(S)L18
10 FILES SEARCHED...
L19 44 (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(S)
L18

=> s (sphingolipid# or sphingo?)(s)L19
L20 37 (SPHINGOLIPID# OR SPHINGO?)(S) L19

=> s L20(s)L2
L21 1 L20(S) L2

=> dup rem L13
PROCESSING COMPLETED FOR L13
L22 9 DUP REM L13 (12 DUPLICATES REMOVED)

=> dup rem L5
PROCESSING COMPLETED FOR L5
L23 4 DUP REM L5 (0 DUPLICATES REMOVED)

=> dup rem L17
PROCESSING COMPLETED FOR L17
L24 3 DUP REM L17 (2 DUPLICATES REMOVED)

=> d ibib abs L22 1-9

L22 ANSWER 1 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2005:254852 USPATFULL
TITLE: Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
Fyrst, Henrik, Alameda, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital & Reaearch Institute at Oakland, Oakland, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005221346	A1	20051006
APPLICATION INFO.:	US 2004-979085	A1	20041101 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-53510, filed on 17 Jan 2002, GRANTED, Pat. No. US 6830881 Continuation-in-part of Ser. No. US 1999-356643, filed on 19 Jul 1999, GRANTED, Pat. No. US 6569666 Continuation-in-part of Ser. No. US 1997-939309, filed on 29 Sep 1997, GRANTED, Pat. No. US 6423527
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1-29

LINE COUNT: 3225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 2 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2004:165347 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital and Research Institute at Oakland, Oakland, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126834	A1	20040701
APPLICATION INFO.:	US 2003-622011	A1	20030716 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-348052, filed on 17 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-53510, filed on 17 Jan 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349582P	20020117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 7285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. Screens for identifying agents that modulate sphingolipid metabolism and/or signaling pathways are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 3 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:312185 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
Fyrst, Henrik, Alameda, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital & Research Institute at Oakland, Oakland, CA, UNITED STATES, 94609-1673 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219782	A1	20031127
APPLICATION INFO.:	US 2003-348052	A1	20030117 (10)

NUMBER DATE
---------- --------
PRIORITY INFORMATION: US 2002-349582P 20020117 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5792
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 4 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:251153 USPATFULL
TITLE: Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
Fyrst, Henrik, Alameda, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital Oakland Research Institute, Oakland, CA, UNITED STATES, 94609-1673 (U.S. corporation)

NUMBER KIND DATE
---------- ------ --------
PATENT INFORMATION: US 2003175939 A1 20030918
US 6830881 B2 20041214
APPLICATION INFO.: US 2002-53510 A1 20020117 (10)
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-356643, filed on 19 Jul 1999, GRANTED, Pat. No. US 6569666
Continuation-in-part of Ser. No. US 1997-939309, filed on 29 Sep 1997, GRANTED, Pat. No. US 6423527
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
LINE COUNT: 3339
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 5 OF 9 USPATFULL on STN
ACCESSION NUMBER: 2003:142956 USPATFULL
TITLE: Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
INVENTOR(S): Saba, Julie D., Oakland, CA, United States

PATENT ASSIGNEE(S): Children's Hospital Oakland Research Institute, Oakland, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6569666	B1	20030527
APPLICATION INFO.:	US 1999-356643		19990719 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-939309, filed on 29 Sep 1997, now patented, Pat. No. US 6423527
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Prouty, Rebecca E.
ASSISTANT EXAMINER: Ramirez, Delia M
LEGAL REPRESENTATIVE: Seed IP Law Group PLLC
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 28 Drawing Figure(s); 26 Drawing Page(s)
LINE COUNT: 2126
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions, methods and kits for diagnosing and treating cancer are provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L22 ANSWER 6 OF 9 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2001519664 MEDLINE
DOCUMENT NUMBER: PubMed ID: 11566853
TITLE: Sphingosine-1-phosphate lyase has a central role in the development of Dictyostelium discoideum.
AUTHOR: Li G; Foote C; Alexander S; Alexander H
CORPORATE SOURCE: Division of Biological Sciences, University of Missouri, Columbia, MO 65211-7400, USA.
CONTRACT NUMBER: GM 53929 (NIGMS)
SOURCE: Development (Cambridge, England), (2001 Sep) Vol. 128, No. 18, pp. 3473-83.
Journal code: 8701744. ISSN: 0950-1991.
PUB. COUNTRY: England: United Kingdom
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
OTHER SOURCE: GENBANK-AF233610
ENTRY MONTH: 200112
ENTRY DATE: Entered STN: 20010924
Last Updated on STN: 20020122
Entered Medline: 20011204

AB Sphingosine-1-phosphate, a product of sphingomyelin degradation, is an important element of signal transduction pathways that regulate cell proliferation and cell death. We have demonstrated additional roles for sphingosine-1-phosphate in growth and multicellular development. The specific disruption in Dictyostelium discoideum of the ***sphingosine*** - ***1*** - ***phosphate*** ***lyase*** ***gene*** , which encodes the enzyme that catalyzes ***sphingosine*** -1-phosphate degradation, results in a ***mutant*** ***strain*** with aberrant morphogenesis, as well as an increase in viability during stationary phase. The absence of sphingosine-1-phosphate lyase affects multiple stages throughout development, including the cytoskeletal architecture of aggregating cells, the ability to form migrating slugs, and the control of cell type-specific gene expression and terminal spore differentiation. This pleiotropic effect, which is due to the loss of sphingosine-1-phosphate lyase, establishes sphingolipids as pivotal regulatory molecules in a wide range of processes in multicellular development.

L22 ANSWER 7 OF 9 LIFESCI COPYRIGHT 2006 CSA on STN

ACCESSION NUMBER: 2002:20855 LIFESCI
TITLE: Elevation of endogenous sphingolipid long-chain base phosphates kills Saccharomyces cerevisiae cells
AUTHOR: Zhang, X.; Skrzypek, M.I.; Lester, R.I.; Dickson, R.I.
CORPORATE SOURCE: Department of Molecular and Cellular Biochemistry and Lucille P. Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA
SOURCE: Current Genetics [Curr. Genet.], (20011200) vol. 40, no. 4, pp. 221-233.
ISSN: 0172-8083.
DOCUMENT TYPE: Journal
FILE SEGMENT: G; K
LANGUAGE: English
SUMMARY LANGUAGE: English
AB ***Sphingolipid*** long-chain base phosphates (LCBPs) regulate cell proliferation, movement and differentiation in higher eukaryotes. To study the function of LCBPs in Saccharomyces cerevisiae, we inactivated LCBP breakdown pathways. Elimination of both the ***Dpl1*** lyase and the Lcb3 phosphatase pathways by ***gene*** deletion was lethal, indicating that these enzymes regulate LCBP levels to prevent accumulation. Lethality was prevented by eliminating the major LCB kinase, Lcb4p, which synthesizes LCBPs, but not by eliminating the minor LCB kinase, Lcb5p. These data imply that death results from an accumulation of LCBPs made by the Lcb4p kinase. By regulating Lcb4 kinase activity, we found that cell death correlates with LCBP accumulation and that C sub(18) dihydrosphingosine-1-P (DHS-P) and C sub(20) DHS-P are most likely the killing molecules. LCB levels were found to be most elevated in a strain lacking Lcb4 kinase, ***Dpl1*** lyase and Lcb3 phosphatase activity. Analysis of ***mutant*** ***strains*** suggests that the C sub(18) and C sub(20) species of LCBPs are preferentially degraded by the Lcb3 phosphate phosphatase, while the ***Dpl1*** lyase prefers C sub(16) DHS-P as a substrate. These and other data indicate the existence of an unknown mechanism(s) for regulating LCB levels. Our results demonstrate that LCBPs may be used in some circumstances to regulate yeast cell growth.

L22 ANSWER 8 OF 9 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 2
ACCESSION NUMBER: 2001:32114 LIFESCI
TITLE: Molecular basis for resistance to the anticancer drug cisplatin in Dictyostelium
AUTHOR: Li, Guochun; Alexander, H.; Schneider, N.; Alexander, S.*
CORPORATE SOURCE: Division of Biological Sciences, University of Missouri, Columbia, MO 65211, USA; E-mail: alexanderst@missouri.edu
SOURCE: Microbiology, (20000900) vol. 146, no. 9, pp. 2219-2227.
ISSN: 1350-0872.
DOCUMENT TYPE: Journal
FILE SEGMENT: K
LANGUAGE: English
SUMMARY LANGUAGE: English
AB The efficacy of the widely used chemotherapeutic drug cisplatin is limited by the occurrence of drug-resistant tumour cells. To fully exploit the potential of this drug in cancer therapy, it is imperative to understand the molecular basis of cisplatin resistance. Using an insertional mutagenesis technique in cells of Dictyostelium discoideum, we have identified six genes which are involved in cisplatin resistance. None of these genes has been previously linked to resistance to this drug. Several of these genes encode proteins that are involved in signal transduction pathways which regulate cell death, cell proliferation or ***gene*** regulation. The resistance of these ***mutant*** ***strains*** is specific for cisplatin, since deletion of these genes does not confer resistance to other DNA-damaging agents. Significantly, the disruption of three of these genes, encoding the ***sphingosine*** - ***1*** - ***phosphate*** ***lyase*** , the RegA cAMP phosphodiesterase and a phosphatidylinositol-4-phosphate 5-kinase, also results in abnormalities in the multicellular development of this organism, although there is no change in the rate of mitotic cell growth. This study has identified previously unsuspected molecular pathways which function in the cellular response to cisplatin and are required for normal morphogenesis, and underscores the complexity of the cellular response to cisplatin. These pathways provide potential targets for modulating the response to this

important drug.

L22 ANSWER 9 OF 9 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 3
ACCESSION NUMBER: 2000:80383 LIFESCI
TITLE: Identification of the First Mammalian Sphingosine Phosphate Lyase Gene and Its Functional Expression in Yeast
AUTHOR: Zhou, J.; Saba, J.D.*
CORPORATE SOURCE: Children's Hospital Oakland Research Institute, Oakland, 94609, California
SOURCE: Biochemical and Biophysical Research Communications, (19980126) vol. 242, no. 3, pp. 502-507.
ISSN: 0006-291X.
DOCUMENT TYPE: Journal
FILE SEGMENT: K
LANGUAGE: English
SUMMARY LANGUAGE: English
AB ***Sphingosine*** -1-phosphate (S-1-P) has been shown to participate in the proliferative signal transduction pathways of mammalian cells. ***Sphingosine*** - ***1*** - ***phosphate*** ***lyase*** (SPL) catalyzes the breakdown of S-1-P. Using the C. elegans SPL nucleotide ***sequence*** , we identified a mouse EST as a putative candidate for the homologous ***gene*** encoding this enzyme. Sequencing of the mouse EST revealed an open reading frame of 1707 nucleotides. This putative mouse SPL ***gene*** is 62% similar and 39% identical to the C. elegans SPL ***gene*** and 59% homologous and 39.6% identical to the yeast SPL ***gene*** . Expression of the mouse SPL ***gene*** in a ***yeast*** ***strain*** - Delta bst1, which carries a deletion of the SPL ***gene*** and is hypersensitive to ***sphingosine*** , restored a ***sphingosine*** -resistant phenotype, suggesting this mouse ***gene*** can functionally complement the yeast defect when expressed. In vitro enzyme assay using extracts from these ***sphingosine*** -resistant transformants confirmed the SPL activities encoded by this mouse cDNA ***clone*** . Northern analysis indicated the mouse SPL ***gene*** is expressed at various levels in different tissues. Chromosomal localization mapped this SPL ***gene*** to Chromosome 10 at 32 cM. Here, we report the identification of the first mammalian ***sphingosine*** phosphate lyase ***gene*** .

=> d ibib abs L23 1-3

L23 ANSWER 1 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2005:254852 USPATFULL
TITLE: Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
Fyrst, Henrik, Alameda, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital & Reaearch Institute at Oakland, Oakland, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005221346	A1	20051006
APPLICATION INFO.:	US 2004-979085	A1	20041101 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-53510, filed on 17 Jan 2002, GRANTED, Pat. No. US 6830881 Continuation-in-part of Ser. No. US 1999-356643, filed on 19 Jul 1999, GRANTED, Pat. No. US 6569666 Continuation-in-part of Ser. No. US 1997-939309, filed on 29 Sep 1997, GRANTED, Pat. No. US 6423527
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092, US
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1-29
LINE COUNT: 3225
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer are

provided. Therapeutic compositions may comprise agents that modulate the expression or activity of a sphingosine-1-phosphate lyase (SPL). Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous SPL. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 2 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2004:165347 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital and Research Institute at Oakland, Oakland, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126834	A1	20040701
APPLICATION INFO.:	US 2003-622011	A1	20030716 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-348052, filed on 17 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-53510, filed on 17 Jan 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349582P	20020117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 7285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. Screens for identifying agents that modulate sphingolipid metabolism and/or signaling pathways are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L23 ANSWER 3 OF 4 USPATFULL on STN
ACCESSION NUMBER: 2003:312185 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
Fyrst, Henrik, Alameda, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital & Research Institute at Oakland, Oakland, CA, UNITED STATES, 94609-1673 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219782	A1	20031127
APPLICATION INFO.:	US 2003-348052	A1	20030117 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349582P	20020117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5792
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs L24 1-3

L24 ANSWER 1 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2004:165347 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital and Research Institute at Oakland, Oakland, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126834	A1	20040701
APPLICATION INFO.:	US 2003-622011	A1	20030716 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-348052, filed on 17 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-53510, filed on 17 Jan 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349582P	20020117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 7285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. Screens for identifying agents that modulate sphingolipid metabolism and/or signaling pathways are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 2 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2003:312185 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES

Fyrst, Henrik, Alameda, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital & Research Institute at Oakland, Oakland, CA, UNITED STATES, 94609-1673 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003219782	A1	20031127
APPLICATION INFO.:	US 2003-348052	A1	20030117 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349582P	20020117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 5792
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. SPL polypeptides, polynucleotides and antibodies are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L24 ANSWER 3 OF 3 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 1
ACCESSION NUMBER: 2002:20855 LIFESCI
TITLE: Elevation of endogenous sphingolipid long-chain base phosphates kills Saccharomyces cerevisiae cells
AUTHOR: Zhang, X.; Skrzypek, M.I.; Lester, R.I.; Dickson, R.I.
CORPORATE SOURCE: Department of Molecular and Cellular Biochemistry and Lucille P. Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY 40536, USA
SOURCE: Current Genetics [Curr. Genet.], (20011200) vol. 40, no. 4, pp. 221-233.
ISSN: 0172-8083.
DOCUMENT TYPE: Journal
FILE SEGMENT: G; K
LANGUAGE: English
SUMMARY LANGUAGE: English
AB ***Sphingolipid*** long-chain base phosphates (LCBPs) regulate cell proliferation, movement and differentiation in higher eukaryotes. To study the function of LCBPs in Saccharomyces cerevisiae, we inactivated LCBP breakdown pathways. Elimination of both the Dpl1 lyase and the Lcb3 phosphatase pathways by ***gene*** deletion was lethal, indicating that these enzymes regulate LCBP levels to prevent accumulation. Lethality was prevented by eliminating the major LCB kinase, Lcb4p, which synthesizes LCBPs, but not by eliminating the minor LCB kinase, Lcb5p. These data imply that death results from an accumulation of LCBPs made by the Lcb4p kinase. By regulating ***Lcb4*** kinase activity, we found that cell death correlates with LCBP accumulation and that C sub(18) dihydrosphingosine-1-P (DHS-P) and C sub(20) DHS-P are most likely the killing molecules. LCB levels were found to be most elevated in a strain lacking ***Lcb4*** kinase, Dpl1 lyase and Lcb3 phosphatase activity. Analysis of ***mutant*** ***strains*** suggests that the C sub(18) and C sub(20) species of LCBPs are preferentially degraded by the Lcb3 phosphate phosphatase, while the Dpl1 lyase prefers C sub(16) DHS-P as a substrate. These and other data indicate the existence of an unknown mechanism(s) for regulating LCB levels. Our results demonstrate that LCBPs may be used in some circumstances to regulate yeast cell growth.

=> d ibib abs L9

L9 ANSWER 1 OF 1 USPATFULL on STN
ACCESSION NUMBER: 2004:165347 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital and Research Institute at Oakland, Oakland, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126834	A1	20040701
APPLICATION INFO.:	US 2003-622011	A1	20030716 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-348052, filed on 17 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-53510, filed on 17 Jan 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349582P	20020117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 7285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. Screens for identifying agents that modulate sphingolipid metabolism and/or signaling pathways are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d ibib abs L21

L21 ANSWER 1 OF 1 USPATFULL on STN
ACCESSION NUMBER: 2004:165347 USPATFULL
TITLE: Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
INVENTOR(S): Saba, Julie D., Oakland, CA, UNITED STATES
PATENT ASSIGNEE(S): Children's Hospital and Research Institute at Oakland, Oakland, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004126834	A1	20040701
APPLICATION INFO.:	US 2003-622011	A1	20030716 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-348052, filed on 17 Jan 2003, PENDING Continuation-in-part of Ser. No. US 2002-53510, filed on 17 Jan 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-349582P	20020117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 7285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions, methods and kits for diagnosing and treating cancer and muscular disorders are provided. Therapeutic compositions may comprise agents that modulate sphingolipid metabolism and/or signaling pathways. Such compositions may be administered to a mammal afflicted with cancer. Diagnostic methods and kits may employ an agent suitable for detecting alterations in endogenous genes involved in sphingolipid metabolism. Such methods and kits may be used to detect the presence of a cancer or to evaluate the prognosis of a known disease. Screens for identifying agents that modulate sphingolipid metabolism and/or signaling pathways are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

L1 QUE ((MUTANT(W) YEAST(W) STRAIN#) OR (MUTANT(W) STRAIN#) OR (YE

L2 154230 S L1
L3 351 S (SPHINGOLIPID# OR SPHINGO?)(S)L2
L4 5440 S (SPHK1 OR SK1 OR (SPHINGOSINE(W)KINASE?))
L5 4 S L3(S)L4
L6 970 S (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(
L7 442 S EXPRESS?(S)L6
L8 234 S (SPHINGOLIPID# OR SPHINGO?)(S)L7
L9 1 S L8(S)L2
L10 442 S ((DIHYDROSPHINGOSINE-1-PHOSPHATE(W)LYASE) OR (SPHINGOSINE-1-P
L11 172 S (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(
L12 21 S L2(S)L11
L13 21 S (SPHINGOLIPID# OR SPHINGO?)(S)L12
L14 94558 S ((SPHINGOSINE(W)KINASE#)OR SK OR LCB4)
L15 16881 S (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(
L16 463 S (SPHINGOLIPID# OR SPHINGO?)(S)L15
L17 5 S L16(S)L2
L18 223 S ((SPHINGOSINE-1-PHOSPHATE(W)PHOSPHATASE#) OR (DIHYDROSPHINGO
L19 44 S (GENE OR SEQUENCE OR POLYNUCLEOTIDE OR CLONE OR RECOMBINANT)(
L20 37 S (SPHINGOLIPID# OR SPHINGO?)(S)L19
L21 1 S L20(S)L2
L22 9 DUP REM L13 (12 DUPLICATES REMOVED)
L23 4 DUP REM L5 (0 DUPLICATES REMOVED)
L24 3 DUP REM L17 (2 DUPLICATES REMOVED)

=> log y